2 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jun 24▼ MACD Negative CrossoverHistogram -0.3477, negative momentum
Jun 23▼ MACD Negative CrossoverHistogram -0.2351, negative momentum
About Innospec Inc.
Headquartered within the basic materials sector, Innospec Inc. focuses on Specialty Chemicals services and products. Innospec Inc. develops, manufactures, blends, markets, and supplies specialty chemicals in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. Valued at $2.08B, IOSP is a mid-cap name in its sector. The company operates through three segments: Performance Chemicals, Fuel Specialties, and Oilfield Services.
Premium feature
News & analytics is part of Premium.
Every headline runs through our finance-grade sentiment engine, so you see the mood of the market on each ticker before you read a single article. Plus the full analyst consensus and target-price upside, refreshed daily.
Per-headline sentiment, scored by a finance-tuned model
See exactly where the price sits versus its 150-day moving average, the live RSI reading, MACD momentum, and volume context, for any ticker, every day.
Innospec Inc. holds $289.1M in cash against $50.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $12.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 8.7%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.0% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $1.96B (2022) to $1.78B (2025).
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Innospec Inc.'s trajectory.